Physician profile
Edwin T Castaneda
NPI 1063412385
$2,434.84
in general payments reported to CMS, 2019-2025
24 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $373 · 2021: $177 · 2022: $182 · 2023: $630 · 2024: $589 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $349.74 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $298.48 | 2019-2020 | |
| Glaxosmithkline, LLC. | $214.49 | 2023-2025 | Arexvy, Shingrix |
| Boston Scientific Corporation | $188.11 | 2024-2025 | Axios, Watchman Access System |
| Amarin Pharma, INC. | $177.01 | 2020-2022 | |
| Lilly USA, LLC | $150.10 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Vertos Medical, INC. | $147.94 | 2023 | Mild Device Kit |
| Amgen INC. | $110.18 | 2024-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $108.52 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $106.81 | 2021-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $68.57 | 2019-2022 | |
| Inspire Medical Systems, INC. | $64.96 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $60.96 | 2024-2025 | |
| Medtronic, INC. | $53.54 | 2021-2023 | Interstim |
| Astellas Pharma US INC | $52.59 | 2020-2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $48.40 | 2021-2024 | Eliquis |
| Pfizer INC. | $47.21 | 2021-2024 | |
| Novo Nordisk INC | $40.00 | 2020-2024 | Ozempic, Rybelsus |
| Amneal Pharmaceuticals LLC | $36.50 | 2022 | |
| Nevro Corp. | $27.92 | 2024 | Senza |
| Phathom Pharmaceuticals, INC. | $26.91 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $21.33 | 2022 | |
| Abbott Laboratories | $17.85 | 2022 | |
| Eisai INC. | $16.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Castaneda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.